Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter Financial Results on August 9

Rhea-AI Summary

Avadel Pharmaceuticals plc (Nasdaq: AVDL) announced a conference call on August 9, 2022, at 8:00 a.m. ET to discuss its corporate update and financial results for Q2 2022, which ended on June 30. Investors can join the call by dialing (833) 630-0586 (U.S.) or (412) 317-1827 (International). A live audio webcast will also be available on the company's investor relations website, with a replay archived for 90 days. Avadel focuses on innovative drug solutions, with LUMRYZ, an investigational sodium oxybate formulation for narcolepsy, as its lead candidate.

Positive

• Upcoming conference call to discuss Q2 2022 financial results and corporate update.
• LUMRYZ, focusing on EDS and cataplexy in narcolepsy, showcases innovative drug delivery technology.

Negative

• None.

DUBLIN, Ireland, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:00 a.m. ET on Tuesday, August 9, 2022, to provide a corporate update and discuss the Company's financial results for the second quarter ended June 30, 2022.

To access the conference call, investors are invited to dial (833) 630-0586 (U.S.) or (412) 317-1827 (International). When joining the call, please ask to join the Avadel Pharmaceuticals call. A live audio webcast can be accessed by visiting the investor relations section of the Company’s website, www.avadel.com. A replay of the webcast will be archived on Avadel’s website for 90 days following the event.

About Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Our current lead drug candidate, LUMRYZ, is an investigational formulation of sodium oxybate leveraging our proprietary drug delivery technology and designed to be taken once at bedtime for the treatment of EDS and cataplexy in adults with narcolepsy. For more information, please visit www.avadel.com.

Investor Contact:
Courtney Turiano
Stern Investor Relations, Inc.
Courtney.Turiano@sternir.com 
(212) 698-8687

Media Contact:
Gabriella Greig
Real Chemistry
ggreig@realchemistry.com 
(203) 249-2688

FAQ

When is Avadel Pharmaceuticals' next earnings call?

The next earnings call will be held on August 9, 2022, at 8:00 a.m. ET.

What financial results will Avadel Pharmaceuticals discuss on August 9, 2022?

Avadel Pharmaceuticals will discuss its financial results for the second quarter ended June 30, 2022.

What is LUMRYZ by Avadel Pharmaceuticals?

LUMRYZ is an investigational formulation of sodium oxybate aimed at treating excessive daytime sleepiness and cataplexy in adults with narcolepsy.

How can I access the Avadel Pharmaceuticals conference call?

Investors can access the call by dialing (833) 630-0586 (U.S.) or (412) 317-1827 (International), or through a live audio webcast on the company's website.